MGD007 is a Dual-Affinity Re-Targeting (DART) protein in development to treat colorectal cancer. The company will receive a $5m milestone payment from Servier, France’s largest privately-held pharmaceutical company,
The FDA concluded that the company’s testosterone product is therapeutically equivalent to AbbVie’s AndroGel 1% and can be substituted with the full expectation that it will produce the
Flonase is the first and only OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms, including runny nose, sneezing, itchy nose, nasal congestion and
The filing of the application will follow the Article 58 procedure, which enables the EMA to evaluate the quality, safety and efficacy of a candidate vaccine, or medicine,
Malignant hyperthermia is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. The FDA had granted orphan drug designated to Ryanodex in
The new product, which will be launched after Health Canada approval, uses a patented delivery system that provides technical advantages over existing alternatives and will be used in
NPC is a rare disease seen mostly of children who are afflicted with Alzheimer-like symptoms. According to the company, the licence also covers other diseases and disorders relying
According to the company, Plegridy can be taken by injection once every two weeks and administered under the skin with a prefilled auto-injector. Biogen Idec chief executive officer
The company also announced that it has received an additional commitment from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to
Under the deal, both the firms will jointly develop and commercialize Opdivo (nivolumab) and Yervoy (ipilimumab) across a broad range of tumor types. Development costs and commercial profits
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.